Arbutus Biopharma Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABUS Nasdaq 2830 www.arbutusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arbutus Biopharma Corporation

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside - Jul 22nd, 2026 3:08 pm
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine - Jul 20th, 2026 9:09 am
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances - Jul 17th, 2026 4:07 am
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Jul 16th, 2026 12:41 pm
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - Jul 16th, 2026 5:30 am
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks - Jul 9th, 2026 4:11 pm
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Jul 7th, 2026 12:28 pm
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results - Jun 13th, 2026 12:06 pm
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 13th, 2026 5:30 am
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals - May 4th, 2026 12:49 am
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - May 1st, 2026 9:32 am
Moderna Q1 2026 earnings beat on international COVID vaccine sales - May 1st, 2026 7:05 am
Moderna sees revenue bump from international COVID vaccine sales - May 1st, 2026 6:27 am
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - May 1st, 2026 3:22 am
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Apr 23rd, 2026 1:29 am
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Apr 17th, 2026 7:58 am
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - Apr 15th, 2026 5:30 am
Arbutus: Q4 Earnings Snapshot - Mar 23rd, 2026 5:39 am
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - Mar 23rd, 2026 5:30 am
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook - Mar 7th, 2026 4:13 pm